Ana Paula de A Boleti, Breno Emanuel F Frihling, Patrícia Souza E Silva, Pedro Henrique de O Cardoso, Luiz Filipe R N de Moraes, Thiago Antônio A Rodrigues, Maria Eduarda Freitas Biembengute, Hector Henrique F Koolen, Ludovico Migliolo
Journal: Neuroscience and biobehavioral reviews 2022;132():1214-1228
PMID: 33031814
Epilepsy is a chronic neurological disease characterized by recurrent epileptic seizures. Studies have shown the complexity of epileptogenesis and ictogenesis, in which immunological processes and epigenetic and structural changes in neuronal tissues have been identified as triggering epilepsy. Cannabidiol (CBD) is a major active component of the Cannabis plant and the source of CBD-enriched products for the treatment of epilepsy and associated diseases. In this review, we provide an up-to-date discussion on cellular and molecular mechanisms triggered during epilepsy crises, and the phytochemical characteristics of CBD that make it an attractive candidate for controlling rare syndromes, with excellent therapeutic properties. We also discuss possible CBD anticonvulsant mechanisms and molecular targets in neurodegenerative disorders and epilepsy. Based on these arguments, we conclude that CBD presents a biotecnological potential in the anticonvulsant process, including decreasing dependence on health care in hospitals, and could make the patient's life more stable, with regard to neurological conditions.
Copyright © 2020 Elsevier Ltd. All rights reserved.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.